Novartis Vaccines & Diagnostics, Gmbh

Chiron Corporation

Silence Therapeutics Gmbh

Joerg Kaufmann

Christoph Reinhard

Greg Harrowe

Giulia C Kennedy

Vivien W Chan

Sanmao Kang

Jaime A Escobedo

Filippo M Randazzo

Pablo Dominguez Garcia

Hong Xin

George Lamson

Julie Sudduth-Klinger

Rhonda Hansen

Edward J Moler

Klaus Giese

Anne B Jefferson

Venkatakrishna Shyamala

Hamiduddin Khoja

The present invention is related to the use of VEGFR1 or of a nucleic acid coding for VEGFR1 as a biomarker in a method for the treatment of a subject, wherein the method for the treatment comprises administering to the subject a PKN3 inhibitor.

Use of VEGFR1 as a biomarker

A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.

Genes differentially expressed in breast cancer

The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.

Gene products differentially expressed in cancerous cells

HX2004-6 polypeptide expressed in cancerous cells

A human gene termed CIF130 and its expression products can alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell. Methods of treating disorders involving alterations in the regulation of mitosis or cell cycle progression utilize the gene and its expression product. Genes whose expression is dependent upon CIF130 expression can be identified.

CIF130 inhibits cell cycle progression

The invention features methods for detection of metastatic and potentially metastatic cancerous cells by detection of expression of a gland-specific Ets transcription factor (GSEF) sequence, which encodes an Ets-domain containing protein. The invention also features methods and compositions for modulation of the polypeptide and/or gene activity for prophylactic and therapeutic purposes, such as inhibition of progression of a cell to a metastatic cancerous cell.

Methods for determining metastatic potential of breast cancer cells by detecting GSEF gene product expression

Human CIF130 polypeptides

Growing community of inventors

Berlin, Germany

Joerg Kaufmann